2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q.Post author:alarpharmPost published:21 . 4 . 2022Post category:Media releases You Might Also Like 2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434. 9 . 8 . 2021 2020/08/03 ALA -1000 Receive notice of patent allowance from the IP Australia. 25 . 8 . 2020 2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6 13 . 5 . 2022 2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B 26 . 7 . 2023 2023/10/12 ALA-2000 has received a notice of allowance from Taiwan Intellectual Property Office (TIPO) after examination. (Patent Application No. 108147847) 29 . 2 . 2024
2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434. 9 . 8 . 2021
2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6 13 . 5 . 2022
2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B 26 . 7 . 2023
2023/10/12 ALA-2000 has received a notice of allowance from Taiwan Intellectual Property Office (TIPO) after examination. (Patent Application No. 108147847) 29 . 2 . 2024